EPPPAF: Prevalence of Non-traumatic Musculoskeletal Disorders in the French Paragliding Pilots Population

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05777096
Collaborator
(none)
26,000
3

Study Details

Study Description

Brief Summary

The main objective is to determine the prevalence of non-traumatic pathologies in the paragliding population using the Nordic type questionnaire.

The paragliding pilots population frequently evoque pathologies, discomfort, or pain in the course of their practice. Said pain and discomfort, though unerelated any form of accident, seem to have an impact on the pilots' flying and their participation in daily life.

However, no epidemiological data are available in the literature. We hypothesize the existence of non-traumatic disorders and it seems interesting to quantify the extent of the phenomenon. The results of this study might encourage the proposition of preventive measures in order to minimize a potential risk factor for paragliding accidents, and participation restrictions.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Standardised Nordic questionnaires

Detailed Description

In this cross-sectional descriptive epidemiological survey, we wish to quantify epidemiological parameters such as the prevalence of pathologies and their consequences in the activities of daily life.

For this purpose, an email containing the link to answer the online questionnaire will be sent to all the licensees.

The link of the questionnaire will be sent directly to all clubs in each league.

The main objective is to calculate the prevalence with descriptive statistics. The primary outcome is the prevalence of non-traumatic pathology in paragliding pilots that had registered to the French Paragliding federation (FFVL) in 2022.

The prevalence will be infered from the IRSST Standardised Nordic Questionnaire with the following formula : Prevalence = (FS4+FS6=yes and FS2=no ) divided by the total number of respondents.

FS4 item "Yes" = pain in the last 12 months FS6 item "Yes" = activity limitations) FS2 item "No" = Non-traumatic disorders

This corresponds to having felt pain in the body region indicated, at least once during the last 12 months, as well as a restriction of participation following this pain, but without having suffered trauma in the area.

For the secondary outcomes will aim at exploring several hypotheses related to personal and environmental factors that could be correlated to the incidence of the nontraumatic disorders. They will be calculated with bivariate descriptive statistics using the Pvalue.io software.

Study Design

Study Type:
Observational
Anticipated Enrollment :
26000 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Prevalence of Non-traumatic Musculoskeletal Disorders in the French Paragliding Pilots Population
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
registered

Paragliding pilots over the age of 18. Registered at the "Fédération Française de Vol Libre" (FFVL) in the year 2022 and/or 2023 Paragliding in the year 2022 and/or 2023

Diagnostic Test: Standardised Nordic questionnaires
participants will complete the SNQ online. Estimated time of participation per person: 15 minutes to fill in the questionnaires

Outcome Measures

Primary Outcome Measures

  1. Prevalence of non-traumatic pathologies in the paragliding pilot population [Cross sectional study. Each participant is evaluated for 15 minutes (estimated time of completion of the questionnaire)]

    The prevalence will be calculated using the IRSST's Standardised Nordic Questionnaire. Prevalence = (FS4+FS6=yes and FS2=no ) on total number of respondents. This prevalence will be calculated on the Population Health, with the FS4 and FS6 items. And to be more specific about atraumatic pathologies, we will add that it is necessary to have answered "no" to the FS2 item. This corresponds to having felt pain in the body region indicated, at least once during the last 12 months, as well as a restriction of participation following this pain, but without having undergone trauma in the area concerned.

Secondary Outcome Measures

  1. Correlations between prevalence, a body area, restriction of participation in paragliding and individual characteristics of participants [Cross sectional study. Each participant is evaluated for 15 minutes (estimated time of completion of the questionnaire)]

    Correlation analysis (univariate and bivariate) between responses to different questions to test for a potential association between variables

  2. Paragliders' beliefs about the origin of their pain. [Cross sectional study. Each participant is evaluated for 15 minutes (estimated time of completion of the questionnaire)]

    Number of respondents with musculoskeletal disorder (FS9=yes)/total number of positive cases ((FS4+FS6=yes and FS2=no)

  3. Prevalence of injuries sustained during a paragliding accident [Cross sectional study. Each participant is evaluated for 15 minutes (estimated time of completion of the questionnaire)]

    Number of respondents with musculoskeletal disorder due to accident/total number of pain positive cases and participation restriction ((FS4+FS6=yes and FS2.3=yes)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • over 18 years old

  • Registered with the FFVL for the year 2022 and/or 2023

  • Paragliding in the year 2022 and/or 2023

Exclusion Criteria:
  • Adults not able to express their consent

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Grenoble

Investigators

  • Principal Investigator: Thomas LATHIERE, Département de kinésithérapie, 175 avenue centrale 38400 Saint Martin d'Hères

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT05777096
Other Study ID Numbers:
  • 2023-A00131-44
First Posted:
Mar 21, 2023
Last Update Posted:
Mar 21, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Grenoble
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 21, 2023